Risk Factors and Long-term Impact of ICIs

NCT05754983 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

1000

Enrollment

OTHER

Sponsor class

Conditions

Malignant Neoplasm

Interventions

DRUG: Solid tumor patients receiving immunotherapy for the first time were included in the study

Sponsor

First Affiliated Hospital Xi'an Jiaotong University